Solventum’s (SOLV) “Buy” Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Solventum (NYSE:SOLV) in a report published on Monday,Benzinga reports. The firm currently has a $95.00 target price on the stock.

SOLV has been the topic of several other research reports. Piper Sandler boosted their price target on Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Mizuho set a $113.00 price objective on Solventum in a research report on Thursday, August 6th. BMO Capital Markets initiated coverage on Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 target price on the stock. KeyCorp lifted their target price on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Wedbush boosted their target price on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Solventum currently has a consensus rating of “Moderate Buy” and an average price target of $92.80.

Solventum Stock Down 1.2%

Shares of NYSE:SOLV opened at $88.98 on Monday. Solventum has a 1-year low of $62.38 and a 1-year high of $94.16. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. The stock has a market cap of $15.15 billion, a P/E ratio of 10.88, a P/E/G ratio of 1.40 and a beta of 0.61. The firm has a fifty day moving average price of $85.94 and a 200 day moving average price of $76.88.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same period in the previous year, the business posted $1.69 earnings per share. Solventum’s quarterly revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Sell-side analysts predict that Solventum will post 7.23 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SOLV. Independent Franchise Partners LLP increased its position in Solventum by 19.0% during the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after purchasing an additional 2,456,451 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Solventum by 20.0% in the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after buying an additional 763,308 shares during the period. Diamond Hill Capital Management Inc. boosted its stake in shares of Solventum by 152.2% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after buying an additional 1,272,921 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Solventum in the second quarter valued at approximately $150,066,000. Finally, Norges Bank acquired a new position in Solventum during the fourth quarter worth $147,467,000.

Solventum Company Profile

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.